Skip to content
10-Q

Quarterly Report

eFFECTOR Therapeutics, Inc.

0000950170-24-056859

← back to feed
Filed
May 9, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · Apr 30, 2024 4.7M sh
Shares Diluted Q1 2024 · Mar 31, 2024 4.08M sh
Shares Diluted restated Q1 2024 · Mar 31, 2023 1.68M sh
Capex Q1 2024 · Mar 31, 2024 $0
Capex Q1 2024 · Mar 31, 2023 $13K
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$7.28M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$7.64M
Short Term Investments Q1 2024 · Mar 31, 2024 $9.88M
Short Term Investments Q1 2024 · Dec 31, 2023 $3.5M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $15.51M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $14.88M
Stockholders Equity Q1 2024 · Mar 31, 2024 $827K
Stockholders Equity Q1 2024 · Dec 31, 2023 −$5.8M
Stockholders Equity Q1 2024 · Mar 31, 2023 −$4.81M
Stockholders Equity Q1 2024 · Dec 31, 2022 $3.9M
Current Liabilities Q1 2024 · Mar 31, 2024 $25.57M
Current Liabilities Q1 2024 · Dec 31, 2023 $25.8M
Total Liabilities Q1 2024 · Mar 31, 2024 $26.3M
Total Liabilities Q1 2024 · Dec 31, 2023 $26.34M
Current Assets Q1 2024 · Mar 31, 2024 $26.25M
Current Assets Q1 2024 · Dec 31, 2023 $19.84M
Total Assets Q1 2024 · Mar 31, 2024 $27.13M
Total Assets Q1 2024 · Dec 31, 2023 $20.54M
Eps Diluted Q1 2024 · Mar 31, 2024 −$2.16
Eps Diluted restated Q1 2024 · Mar 31, 2023 −$5.96
Eps Basic Q1 2024 · Mar 31, 2024 −$2.16
Eps Basic restated Q1 2024 · Mar 31, 2023 −$5.96
Sga Expense Q1 2024 · Mar 31, 2024 $3.09M
Sga Expense Q1 2024 · Mar 31, 2023 $2.93M
Rd Expense Q1 2024 · Mar 31, 2024 $5.31M
Rd Expense Q1 2024 · Mar 31, 2023 $6.61M
Net Income Q1 2024 · Mar 31, 2024 −$8.83M
Net Income Q1 2024 · Mar 31, 2023 −$10.01M
Operating Income Q1 2024 · Mar 31, 2024 −$8.4M
Operating Income Q1 2024 · Mar 31, 2023 −$9.54M
Revenue Q1 2024 · Mar 31, 2024 $0
Revenue Q1 2024 · Mar 31, 2023 $0